Clonal evolution with inv (11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia
M Yamamoto, K Kakihana, T Kurosu… - Cancer genetics and …, 2005 - Elsevier
The BCR/ABL tyrosine kinase inhibitor imatinib has shown remarkable efficacy in treating
patients with chronic myelogenous leukemia (CML). In a small portion of patients treated
with imatinib, however, the disease may progress to advanced stages, frequently
accompanied by cytogenetic clonal evolution with the appearance of additional
chromosomal aberrations besides the Philadelphia chromosome. Here we report the
appearance of an inv (11)(p15q22) as a clonal evolution in a CML patient undergoing …
patients with chronic myelogenous leukemia (CML). In a small portion of patients treated
with imatinib, however, the disease may progress to advanced stages, frequently
accompanied by cytogenetic clonal evolution with the appearance of additional
chromosomal aberrations besides the Philadelphia chromosome. Here we report the
appearance of an inv (11)(p15q22) as a clonal evolution in a CML patient undergoing …